X0306 4 2020-07-01 false 0001636422 Health Catalyst, Inc. HCAT 0001780978 Horstmeier Paul C/O HEALTH CATALYST, INC. 3165 MILLROCK DRIVE, #400 SALT LAKE CITY UT 84121 false true false false Chief Operating Officer Common Stock 2020-07-01 4 M false 6004.00 10.80 A 81004.00 D Common Stock 2020-07-01 4 M false 858.00 15.84 A 81862.00 D Common Stock 2020-07-01 4 M false 3888.00 10.30 A 85750.00 D Common Stock 2020-07-01 4 S false 858.00 29.11 D 84892.00 D Common Stock 2020-07-01 4 S false 3588.00 28.83 D 81304.00 D Common Stock 2020-07-01 4 S false 5504.00 28.85 D 75800.00 D Common Stock 2020-07-01 4 S false 500.00 29.79 D 75300.00 D Common Stock 2020-07-01 4 S false 300.00 29.77 D 75000.00 D Stock Option (Right to Buy) 15.84 2020-07-01 4 M false 858.00 0.00 D 2029-02-05 Common Stock 858.00 24142.00 D Stock Option (Right to Buy) 10.80 2020-07-01 4 M false 6004.00 0.00 D 2019-12-25 2028-09-27 Common Stock 6004.00 0.00 D Stock Option (Right to Buy) 10.30 2020-07-01 4 M false 3888.00 0.00 D 2017-12-28 2025-11-09 Common Stock 3888.00 0.00 D The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 22, 2019, in accordance with Rule 10b5-1. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $28.52 to $29.42, inclusive. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $28.52 to $29.51, inclusive. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $29.61 to $30.02, inclusive. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $29.61 to $29.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) through (5). 25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vests in equal monthly installments until the option vests in full on February 05, 2023. 25% of the 6,004 shares underlying the option vested in an annual installment and the remaining balance vested in equal monthly installments until the option was vested in full on December 25, 2019. 25% of the 9,388 shares underlying the option vested in an annual installment and the remaining balance vested in equal monthly installments until the option was vested in full on December 28, 2017. /s/ Daniel Orenstein, as Attorney-in-Fact 2020-07-06